Patents Represented by Attorney Max D. Hensley
  • Patent number: 4920196
    Abstract: Biologically active lymphotoxin polypeptide species, and derivatives, fragments, aggregates and pharmaceutically acceptable salts are provided. The lymphotoxins are substantially homogenous, and are formulated into pharmaceutical compositions. The lymphotoxins are purified to a specific activity of at least 10.sup.6 units/mg protein by using hydrophobic substances and/or immobilized lentil lectin, or with the use of other chromatographic processes such as ion exchange chromatography, HPLC or gel filtration.
    Type: Grant
    Filed: February 6, 1987
    Date of Patent: April 24, 1990
    Assignee: Genentech, Inc.
    Inventor: Bharat B. Aggarwal
  • Patent number: 4859609
    Abstract: Hybrid receptors are provided that comprise (a) the ligand binding domain of a predetermined receptor and (b) a heterologous reporter polypeptide. The hybrid receptors are useful for convenient and large scale assay of biologically active ligands or their antagonists or agonists.
    Type: Grant
    Filed: April 30, 1986
    Date of Patent: August 22, 1989
    Assignee: Genentech, Inc.
    Inventors: Thomas J. Dull, Heimo Riedel, Axel Ullrich
  • Patent number: 4859600
    Abstract: The production of mature hGH in E coli and Pseudomonas strains transformed by a plasmid which encodes pre hGH (comprising the signal polypeptide and the hormone itself) is described. These prokaryotes process the pre-hGH to cleave the signal sequence and, thereby, produce mature hGH.
    Type: Grant
    Filed: April 26, 1988
    Date of Patent: August 22, 1989
    Assignee: Genentech, Inc.
    Inventors: Gregory L. Gray, Herbert L. Heyneker
  • Patent number: 4857637
    Abstract: The activity of growth-associated receptors is modulated in vivo in a controlled and reproducible fashion by immunizing animals against target growth-associated receptors. This is accomplished by the use of immunogens predetermined to induce primarily agonist or antagonist responses. The immunogens include anti-ligand antibodies and receptor derivatives.
    Type: Grant
    Filed: June 12, 1987
    Date of Patent: August 15, 1989
    Assignee: Genentech, Inc.
    Inventors: R. Glenn Hammonds, David W. Leung, David W. Martin, Jr., Steven A. Spencer, William I. Wood
  • Patent number: 4828830
    Abstract: TNF or LT qualitatively and quantitatively potentiates the anti-viral activity of interferons, thus permitting the use of lower interferon doses to protect uninfected cells from interferon sensitive and relatively insensitive viruses and to selectively kill virus-infected cells.
    Type: Grant
    Filed: January 24, 1986
    Date of Patent: May 9, 1989
    Assignee: Genentech, Inc.
    Inventor: Grace H. W. Wong
  • Patent number: 4760025
    Abstract: A cloned subtilisin gene has been modified at specific sites to cause amino acid substitutions at certain spots in the enzyme. The modified enzyme, preferably produced by Bacillus, is useful in combination with detergents.
    Type: Grant
    Filed: May 29, 1984
    Date of Patent: July 26, 1988
    Assignee: Genencor, Inc.
    Inventors: David A. Estell, James A. Wells
  • Patent number: 4495278
    Abstract: Viruses, particularly hepatitis viruses, in blood clotting enzyme compositions are inactivated with little enzyme activity loss by heating the compositions in the dry state. The novel products which result are therapeutically and diagnostically useful.
    Type: Grant
    Filed: April 27, 1981
    Date of Patent: January 22, 1985
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: William R. Thomas
  • Patent number: 4489167
    Abstract: Carcinoembryonic antigen contains immune determinates in common with .alpha.-acid glycoprotein. Carcinoembryonic antigen-containing compositions are purified by adsorption onto antibody to .alpha.-acid glycoprotein. The purified compositions may be employed as standards in carcinoembryonic antigen assays or in the labelled form as tracers. Intact carcinoembryonic antigen is assayed by a modified sandwich-type immunoassay. Other cancer-associated substances may be identified by searching for high molecular weight analogues of normal proteins.
    Type: Grant
    Filed: June 2, 1981
    Date of Patent: December 18, 1984
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Yukio Ochi, Takashi Hachiya, Tadayoshi Miyazaki, Yoshihiro Kajita
  • Patent number: 4480029
    Abstract: Biological indicators are used to evaluate the effectiveness of virus inactivation conducted on virus-contaminated, protein-containing compositions. The indicators comprise dry protein and a predetermined titer of infectious virus.
    Type: Grant
    Filed: April 27, 1981
    Date of Patent: October 30, 1984
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Gary H. Dolana
  • Patent number: 4479938
    Abstract: Patients having a clotting factor defect can be successfully treated by the administration of a composition containing effective hemostatic amounts of factor VIIa. Preferably, the factor VIIa is substantially free of factors IXa and Xa. Procedures for preparing the above therapeutic compositions are also described.
    Type: Grant
    Filed: June 14, 1982
    Date of Patent: October 30, 1984
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: William R. Thomas
  • Patent number: 4455299
    Abstract: Blood platelet pH is maintained between 6.0 and 7.6 for up to at least five days in relatively low gas permeability containers, e.g., standard polyvinyl chloride containers, by exposing the container to an atmosphere having an oxygen content greater than about 21%.
    Type: Grant
    Filed: November 20, 1981
    Date of Patent: June 19, 1984
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Gerald A. Grode
  • Patent number: 4439421
    Abstract: Gamma globulin concentrates are stabilized against anticomplement activity generation during lyophilization by inclusion in the concentrate of a physiologically acceptable, substantially nonsurface-active hydrophilic macromolecule. The improved concentrates may be safely administered to patients. The main additives to the gamma globulin are a substantially nonsurface-active hydrophilic macromolecule, a protein and a polyol.
    Type: Grant
    Filed: August 30, 1982
    Date of Patent: March 27, 1984
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: John A. Hooper, Samia Mankarious, Catherine R. Liu-Rash
  • Patent number: 4413741
    Abstract: An improved hanger assembly is provided for use with bottles containing liquids, particularly glass vessels for holding liquids to be administered parenterally. The hanger includes a frangibly-activated hinge that biases the rotation of a hook or loop into a position to enable safe and expeditious hanging of the bottle. The assembly is a substantially rigid unitary construction made of material having a substantially uniform thickness, i.e., not having any elements protruding outside of the general profile of the bottle to be hung. The assembly maintains this profile until the frangibly-activated hinge is broken to allow rotation of the hook or loop into a position to permit hanging. Further, use of a frangibly-activated hinge permits the use of design and materials for the hanger assembly which reduce the risks of tearing the hanger and improve the bottle orientation when it is hung.
    Type: Grant
    Filed: December 16, 1981
    Date of Patent: November 8, 1983
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Leon T. Curchack
  • Patent number: 4411795
    Abstract: Lipin particles are removed from aqueous suspension by adsorption on hydrophilic macromolecules substituted with pendant hydrophobic groups. Particularly beneficial results are achieved by use of pendant hydrophobes linked by strongly ionogenic groups to water insoluble carriers.
    Type: Grant
    Filed: February 26, 1981
    Date of Patent: October 25, 1983
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: Wayne P. Olson
  • Patent number: 4397779
    Abstract: Compounds useful as tracers in the radioimmunoassay of xanthine derivatives such as theophylline and pharmacologically related drugs: ##STR1## wherein at least one R.sub.1, R.sub.3, R.sub.7 or R.sub.8 is a radioiodinated radical and wherein, if not substituted by a radioiodinated radical, the remaining R.sub.1, R.sub.3, R.sub.7 or R.sub.8 groups are otherwise identical to the substituents at these positions in the xanthine derivative to be assayed. Ordinarily, R.sub.1 is hydrogen, acetate or methyl; R.sub.3 is methyl; R.sub.7 is hydrogen, acetate or methyl; and R.sub.8 is hydrogen. The tracers are made by linking radioiodinatable or preradioiodinated radicals to the xanthine derivative which is to be assayed. The tracers may be employed in known radioimmunoassay techniques.
    Type: Grant
    Filed: May 28, 1981
    Date of Patent: August 9, 1983
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Ernest V. Groman, Michael D. Cabelli
  • Patent number: 4382083
    Abstract: Patients having a clotting factor defect can be successfully treated by the administration of a composition containing effective hemostatic amounts of factor VIIa. Preferably, the factor VIIa is substantially free of factors IXa and Xa. Procedures for preparing the above therapeutic compositions are also described.
    Type: Grant
    Filed: June 25, 1981
    Date of Patent: May 3, 1983
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: William R. Thomas
  • Patent number: 4376819
    Abstract: A p-nitrophenyl hydrolase contaminant present in Limulus coagulase sources interferes in, i.e., inhibits, coagulase-based assays for endotoxin. The contaminant inhibitor enzyme may be removed from coagulase by physical separation or by selective denaturation, for example by adjusting the pH of a coagulase solution to about from 8.5 to 11. Inhibitor-free coagulase is a novel composition. The coagulase activity of the composition is adjusted to a predetermined level to provide a standardized coagulase reagent for use in endotoxin assays.
    Type: Grant
    Filed: February 23, 1981
    Date of Patent: March 15, 1983
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: R. Clark Brown, Richard Cotter, Susan K. Young
  • Patent number: 4357321
    Abstract: A composition comprising about from 37 to 190 units of factor VII/ml and about from 25 to 80 units of factor VIIa/ml is administered to patients in the treatment of clotting factor inhibitors. The composition may include activated and unactivated clotting factors such as factors IX, IXa, Xa and X.
    Type: Grant
    Filed: May 11, 1981
    Date of Patent: November 2, 1982
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventor: William R. Thomas
  • Patent number: 4357343
    Abstract: A novel amino acid composition is provided for the nutritional maintenance of renal failure patients.
    Type: Grant
    Filed: June 26, 1981
    Date of Patent: November 2, 1982
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: David C. Madsen, Hugh N. Tucker
  • Patent number: 4357310
    Abstract: Nonspecific binding of radioiodinated protein hormones in specific-receptor binding assays is reduced by including a nonionic detergent with the tracer during storage prior to the assay.
    Type: Grant
    Filed: August 8, 1980
    Date of Patent: November 2, 1982
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Catherine T. Chan, Debra A. Gravallese